PLP.L - Polypipe Group plc

LSE - LSE Delayed price. Currency in GBp
587.00
-2.00 (-0.34%)
As of 1:00PM GMT. Market open.
Stock chart is not supported by your current browser
Previous close589.00
Open594.50
Bid586.50 x 0
Ask588.00 x 0
Day's range577.00 - 594.50
52-week range365.00 - 620.00
Volume660,726
Avg. volume380,786
Market cap1.18B
Beta (5Y monthly)0.48
PE ratio (TTM)23.77
EPS (TTM)24.70
Earnings date17 Mar 2020
Forward dividend & yield0.12 (1.96%)
Ex-dividend date29 Aug 2019
1y target est459.00
  • How Does Polypipe Group plc (LON:PLP) Stand Up To These Simple Dividend Safety Checks?
    Simply Wall St.

    How Does Polypipe Group plc (LON:PLP) Stand Up To These Simple Dividend Safety Checks?

    Today we'll take a closer look at Polypipe Group plc (LON:PLP) from a dividend investor's perspective. Owning a strong...

  • £2K to invest? I’d check out these 2 high-flying FTSE 250 growth stocks
    Fool.co.uk

    £2K to invest? I’d check out these 2 high-flying FTSE 250 growth stocks

    These FTSE 250 (INDEXFTSE:UKX) growth stocks are up more than 65% in the last year alone, and are well worth a look.The post £2K to invest? I'd check out these 2 high-flying FTSE 250 growth stocks appeared first on The Motley Fool UK.

  • Is Polypipe Group plc's (LON:PLP) ROE Of 15% Impressive?
    Simply Wall St.

    Is Polypipe Group plc's (LON:PLP) ROE Of 15% Impressive?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • With EPS Growth And More, Polypipe Group (LON:PLP) Is Interesting
    Simply Wall St.

    With EPS Growth And More, Polypipe Group (LON:PLP) Is Interesting

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

  • Estimating The Fair Value Of Polypipe Group plc (LON:PLP)
    Simply Wall St.

    Estimating The Fair Value Of Polypipe Group plc (LON:PLP)

    How far off is Polypipe Group plc (LON:PLP) from its intrinsic value? Using the most recent financial data, we'll take...

  • Should We Worry About Polypipe Group plc's (LON:PLP) P/E Ratio?
    Simply Wall St.

    Should We Worry About Polypipe Group plc's (LON:PLP) P/E Ratio?

    Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...

  • Are Polypipe Group plc’s (LON:PLP) Returns Worth Your While?
    Simply Wall St.

    Are Polypipe Group plc’s (LON:PLP) Returns Worth Your While?

    Today we'll look at Polypipe Group plc (LON:PLP) and reflect on its potential as an investment. Specifically, we'll...

  • Where Polypipe Group plc (LON:PLP) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.

    Where Polypipe Group plc (LON:PLP) Stands In Terms Of Earnings Growth Against Its Industry

    For investors, increase in profitability and industry-beating performance can be essential considerations in an...

  • Here's What We Like About Polypipe Group plc (LON:PLP)'s Upcoming Dividend
    Simply Wall St.

    Here's What We Like About Polypipe Group plc (LON:PLP)'s Upcoming Dividend

    Polypipe Group plc (LON:PLP) stock is about to trade ex-dividend in 4 days time. Investors can purchase shares before...

  • Polypipe Group (LON:PLP) Shareholders Have Enjoyed A 52% Share Price Gain
    Simply Wall St.

    Polypipe Group (LON:PLP) Shareholders Have Enjoyed A 52% Share Price Gain

    Polypipe Group plc (LON:PLP) shareholders might be concerned after seeing the share price drop 10% in the last...

  • Is Polypipe Group (LON:PLP) Using Too Much Debt?
    Simply Wall St.

    Is Polypipe Group (LON:PLP) Using Too Much Debt?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Polypipe Group plc (LON:PLP): Will The Growth Last?
    Simply Wall St.

    Polypipe Group plc (LON:PLP): Will The Growth Last?

    After Polypipe Group plc's (LON:PLP) earnings announcement in December 2018, it seems that analyst expectations are...

  • What Polypipe Group plc's (LON:PLP) ROE Can Tell Us
    Simply Wall St.

    What Polypipe Group plc's (LON:PLP) ROE Can Tell Us

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Does This Valuation Of Polypipe Group plc (LON:PLP) Imply Investors Are Overpaying?
    Simply Wall St.

    Does This Valuation Of Polypipe Group plc (LON:PLP) Imply Investors Are Overpaying?

    Today we will run through one way of estimating the intrinsic value of Polypipe Group plc (LON:PLP) by taking the...

  • Is Polypipe Group plc (LON:PLP) A Smart Pick For Income Investors?
    Simply Wall St.

    Is Polypipe Group plc (LON:PLP) A Smart Pick For Income Investors?

    Could Polypipe Group plc (LON:PLP) be an attractive dividend share to own for the long haul? Investors are often drawn...

  • Here's Why I Think Polypipe Group (LON:PLP) Might Deserve Your Attention Today
    Simply Wall St.

    Here's Why I Think Polypipe Group (LON:PLP) Might Deserve Your Attention Today

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • What Does Polypipe Group plc's (LON:PLP) P/E Ratio Tell You?
    Simply Wall St.

    What Does Polypipe Group plc's (LON:PLP) P/E Ratio Tell You?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll look at Polypipe Group plc's (LON:PLP) P/E ratio and reflect on what it tells us about the company's share...

  • EQS Group

    Edison Investment Research Limited: Edison issues outlook on China Water Affairs Group (855)

    Edison Investment Research Limited 16-Apr-2019 / 10:03 GMT/BST * * *London, UK, 16 April 2019Edison issues outlook on China Water Affairs Group (855)We believe China Water Affairs Group's (CWA) strong financial position (net debt/equity FY18 c 70%) and impressive track record of generating returns for shareholders should enable it to exploit the favourable market conditions and allow for a continuation of its strong growth profile. Following the recent acquisition of 29.5% of Kangda International, CWA's market valuation appears undemanding compared to its peers despite its track record of delivering attractive returns for its shareholders.Applying peer group average multiples would indicate a valuation of c HK$11.4 per share (up HK$0.9 per share since we last published in December 2018), for CWA, c HK$3 per share above the current share price. At HK$8.2 per share, CWA trades on a PEG ratio of only 0.6x versus 1.6x for its peers. Applying an undemanding PEG ratio of 1.0x would indicate a valuation of HK$13.0 per share. Our DCF points to a valuation of HK$11.9 per share. Click here to view the full report.All reports published by Edison are available to download free of charge from its website www.edisongroup.comAbout Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.Edison is authorised and regulated by the Financial Conduct Authority.Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.For more information please contact Edison:Graeme Moyse, +44 (0)20 3077 5700 Industrials@edisongroup.comLearn more at www.edisongroup.com and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_Res YouTube www.youtube.com/edisonitv * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

  • EQS Group

    Edison issues outlook on Primary Health Properties (PHP)

    Edison Investment Research Limited 10-Apr-2019 / 13:28 GMT/BST * * *London, UK, 10 April 2019Edison issues outlook on Primary Health Properties (PHP)Primary Health Properties' (PHP's) all-share merger with MedicX completed as planned on 14 March 2019, creating the leading primary healthcare investor in the UK and the Republic of Ireland. Our earnings forecasts immediately benefit from cost efficiencies, while the combination of two high-quality portfolios creates a scale platform, well placed to profitably address the substantial investment needs of the primary healthcare sectors in both countries.PHP offers an attractive and growing dividend, fully covered by earnings. Income visibility is strong, with revenues supported by secure, long-term income, substantially subject to upward-only review, with little exposure to the economic cycle, or fluctuations in occupancy. The complementary nature of the merger and added scale enhance future growth prospects. Click here to view the full report.All reports published by Edison are available to download free of charge from its website www.edisongroup.comAbout Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.Edison is authorised and regulated by the Financial Conduct Authority.Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.For more information please contact Edison:Martyn King, +44 (0)20 3077 5745 Andrew Mitchell, +44 (0)20 3681 2500 financials@edisongroup.comLearn more at www.edisongroup.com and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_Res YouTube www.youtube.com/edisonitv * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

  • Does Polypipe Group plc's (LON:PLP) 8.4% Earnings Growth Reflect The Long-Term Trend?
    Simply Wall St.

    Does Polypipe Group plc's (LON:PLP) 8.4% Earnings Growth Reflect The Long-Term Trend?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Assessing Polypipe Group plc's (LON:PLP) past track record of performance is an insightful exercise for investors. It allows...

  • EQS Group

    Edison Investment Research Limited: Edison issues outlook on Telix Pharmaceuticals (TLX)

    Edison Investment Research Limited 03-Apr-2019 / 10:56 GMT/BST * * *London, UK, 3 April 2019Edison issues outlook on Telix Pharmaceuticals (TLX)Telix Pharmaceuticals has added significant value by acquiring ANMI, the developer of its TLX591-CDx prostate cancer imaging kit and underlying 'cold kit' technology. It also announced plans to accelerate its TLX591 prostate cancer therapeutic into Phase III, based on a third-party review of clinical data that formed part of the Atlab acquisition in September. Following the ANMI acquisition we increase our valuation to A$380m (vs A$303m) or A$1.74 per share (vs A$1.43 per share). FDA agreement to the TLX591 Phase III design would likely prompt a further valuation uplift.We lift our valuation to A$380m (vs A$303m) or A$1.74/share (vs A$1.43/share). We have revised our model for the ANMI acquisition and the resultant move to 100% of global rights to TLX591-CDx (vs the prior US-only JV). We assume ex-US sales will match our US peak sales forecast of US$80m and an operating profit margin (before royalties) of 35% in the US and 25% in other territories. We will review our valuation if Telix gains FDA agreement to progress TLX591 to Phase III. Click here to view the full report.All reports published by Edison are available to download free of charge from its website www.edisongroup.comAbout Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.Edison is authorised and regulated by the Financial Conduct Authority.Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.For more information please contact Edison:Dennis Hulme, +61 (0)2 8249 8345 John Savin, +44 (0)20 3077 5735 healthcare@edisongroup.com Learn more at www.edisongroup.com and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_Res YouTube www.youtube.com/edisonitv * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

  • EQS Group

    Edison Investment Research Limited: Edison issues outlook on Polypipe (PLP)

    Edison Investment Research Limited 02-Apr-2019 / 12:08 GMT/BST * * *London, UK, 2 April 2019Edison issues outlook on Polypipe (PLP)Polypipe's rating is currently slightly ahead of its sector, but this overlooks the company's positioning in long-term growth segments, in our view. The FY18 trading performance was noticeably stronger in H2, though margin progression was constrained by short-term production inefficiencies in certain areas. Management provide a clear and consistent message regarding business focus under a refreshed, growth-oriented strategy.After a weak close to 2018, Polypipe's share price has rebounded strongly (being up x15% ytd and also c 8% over the last 12 months) though is now off the 432.60p high seen just before the FY18 results announcement. We note that some but not all of the quoted UK housebuilders have also had a strong start to the year in share price terms and the long-term structural UK housing shortage theme is intact. Polypipe's modest P/E premium compared to UK listed peers does not reflect its leading market share positions and strategic positioning to develop further in our view. Click here to view the full report.Subscribe to Edison's content to receive reports by email. All reports published by Edison are free-to-access and available on the website.About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.Edison is authorised and regulated by the Financial Conduct Authority.Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.For more information please contact Edison:Toby Thorrington, +44 (0)20 3077 5721industrials@edisongroup.com Learn more at www.edisongroup.com and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_Res YouTube www.youtube.com/edisonitv * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more